258 related articles for article (PubMed ID: 22517701)
1. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
2. Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Inal A; Ciltas A; Yildiz R; Berk V; Kos FT; Dane F; Unek IT; Colak D; Ozdemir NY; Buyukberber S; Gumus M; Ozkan M; Isikdogan A
Asian Pac J Cancer Prev; 2012; 13(5):1841-4. PubMed ID: 22901133
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
Tas F; Karabulut S; Ciftci R; Sen F; Sakar B; Disci R; Duranyildiz D
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1163-71. PubMed ID: 24647734
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin.
You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
BMC Cancer; 2019 Jan; 19(1):10. PubMed ID: 30611225
[TBL] [Abstract][Full Text] [Related]
7. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
Stemmler J; Stieber P; Szymala AM; Schalhorn A; Schermuly MM; Wilkowski R; Helmberger T; Lamerz R; Stoffregen C; Niebler K; Garbrecht M; Heinemann V
Onkologie; 2003 Oct; 26(5):462-7. PubMed ID: 14605463
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
Park I; Choi SJ; Kim YS; Ahn HK; Hong J; Sym SJ; Park J; Cho EK; Lee JH; Shin YJ; Shin DB
Cancer Res Treat; 2016 Oct; 48(4):1264-1273. PubMed ID: 27034148
[TBL] [Abstract][Full Text] [Related]
10. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Khalil MA; Qiao W; Carlson P; George B; Javle M; Overman M; Varadhachary G; Wolff RA; Abbruzzese JL; Fogelman DR
Invest New Drugs; 2013 Oct; 31(5):1375-83. PubMed ID: 23645398
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Dikiltas M; Unek IT; Colak D; Elkiran ET; Helvaci K; Geredeli C; Dane F; Balakan O; Kaplan MA; Durnali AG; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Kucukoner M; Ozkan M; Uncu D; Benekli M; Isikdogan A
Neoplasma; 2012; 59(3):297-301. PubMed ID: 22329849
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
[TBL] [Abstract][Full Text] [Related]
13. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
15. Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience.
Lundberg J; Reardon J; Blazer M; Phillips G; Bekaii-Saab T
Med Oncol; 2016 Jan; 33(1):4. PubMed ID: 26696390
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
An SG; Kim DU; Song GA; Jang AL
Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
[TBL] [Abstract][Full Text] [Related]
17. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
Xue P; Zhu L; Wan Z; Huang W; Li N; Chen D; Hu J; Yang H; Wang L
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1653-60. PubMed ID: 25792009
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
[TBL] [Abstract][Full Text] [Related]
20. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
